http://www.biospace.com/BioSpace RSS Generatorhttp://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=2Copyright (C) 2007http://www.biospace.com/news_story.aspx?StoryID=95701&full=1Transaction Provides Substantial Infusion of Cash as Osiris Prepares for Commercial Launch of Prochymal</p><p>COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has entered into a definitive agreement with NuVasive, Inc. (NASDAQ:NUVA) to sell Osiris Osteocel business for up to $85 million in upfront and milestone payments. In a separate agreement worth...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95710&full=1EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq:ADLR - News) announced today that the U.S. Food and Drug Administration (FDA) has communicated to the company that it will not be issuing an action letter on the NDA for Entereg (alvimopan) for postoperative ileus by May 10, 2008, the scheduled PDUFA date. The FDA did not provide a specific date, but informed the company that it expects to issue...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95777&full=1Acquisition Seen as Strategic and Accretive, Adding Management, Manufacturing and Scientific Depth</p><p>NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) announced the acquisition on May 8th of substantially all of the U.S. based assets of BIOMOL International, LP, of Plymouth Meeting, PA, and all of the stock of its two-wholly-owned United Kingdom subsidiaries. BIOMOL is a privately owned...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95711&full=1IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI - News): Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI - News) announced today that it has sold its abbreviated new drug applications (ANDAs) for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals, Inc.</p><p>The sale of these non-core assets provides...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95712&full=1NORWALK, Conn.--(BUSINESS WIRE)--Applera Corporation today announced that its board of directors has formally approved the proposed separation of the Celera Group (NYSE:CRA - News) from Applera's remaining businesses. The separation will be accomplished by means of a redemption of all of the outstanding shares of Applera Corporation - Celera Group tracking stock. In the redemption, each outstanding...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95714&full=1TOKYO & PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY - News) announced that ABILIFY (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia. ABILIFY is now indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in pediatric patients...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95699&full=1RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted a Priority Review of Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).</p><p>The Priority Review designation is intended to expedite...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95715&full=1NEW YORK, May 8 (Reuters) - The chief executive of drugmaker Bristol-Myers Squibb Co bought 100,000 company shares in his first open-market purchase since taking the top post nearly two years ago, according to a regulatory filing on Thursday.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95804&full=1<p> PRINCETON, N.J., May 9 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson has been appointed Chief Executive Officer. Mr. Jackson joined Celator in October 2007 as Head of Commercial Development.</p><p> "We are delighted to have Scott as the new CEO. He brings more than 20 years of pharmaceutical experience, including 10 years of specialty pharmaceutical experience...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95863&full=1May 9, 2008 -- The SFDA will soon introduce new rules that will speed up the IND process for innovative drugs in China. The new procedures will not, apparently, change overall IND standards. However, the SFDA will establish guidelines that distinguish innovative drugs, especially those for unmet needs, from less significant submissions. These innovative INDs will receive first priority at the SFDA...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95784&full=1EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq:ADLR) announced today that the U.S. Food and Drug Administration (FDA) has communicated to the company that it will not be issuing an action letter on the NDA for Entereg (alvimopan) for postoperative ileus by May 10, 2008, the scheduled PDUFA date. The FDA did not provide a specific date, but informed the company that it expects to issue the...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95719&full=1<p> NUTLEY, N.J., May 9 /PRNewswire/ -- Roche today announced one-year results from a new two-year Phase III study showing that ACTEMRA(TM) (tocilizumab) can significantly inhibit progression of structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. The study also demonstrated that ACTEMRA reduces disease signs and symptoms...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95829&full=1SYDNEY, AUSTRALIA and LONDON and NEW CANAAN, CT--(Marketwire - May 09, 2008) - The accrual time for the OVArian TUmor REsponse (OVATURE) clinical study, a Phase III study of the investigational chemosensitizing drug, phenoxodiol, has been extended to facilitate complete patient enrollment in the U.S., Europe, and Australia. Increasing the accrual period allowed decreasing the total number of patients...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95713&full=1NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP - News), announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to palifosfamide in the treatment of Soft Tissue Sarcoma (STS). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95860&full=1<p> CALGARY, May 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") announced today that it has begun patient enrolment in a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95718&full=1<p> EL SEGUNDO, Calif., May 8 /PRNewswire/ -- DaVita Clinical Research(R) (DCR), a Phase I-IV clinical trial research service business specializing in renal-related drug and device research and development for FDA approval, reports it completed 13 Phase-I clinical trials in 2007 and has another 34 active trials in late stage drug development-a company record.</p><p> (Logo: http://www.newscom...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95778&full=1RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has received a notice of no objection from Health Canada for the Companys Clinical Trial Application (CTA) for its defensin mimetic antibiotic compound, PMX-30063. This...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95720&full=1<p> DOYLESTOWN, Pennsylvania and OXFORD, England, May 9 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen's shareholders at a special meeting on 8 May.</p><p> Under the terms of the acquisition...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95759&full=1<p> OSAKA, Japan, and CAMBRIDGE, Mass., May 9 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited, "Takeda", and Millennium Pharmaceuticals, Inc., "Millennium" today announced the successful completion of Takeda's cash tender offer by its wholly-owned subsidiary, Mahogany Acquisition Corp., to acquire all outstanding shares of Millennium common stock for US$25.00 per share.</p><p...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95805&full=1AMITYVILLE, N.Y.--(BUSINESS WIRE)--Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced today that it entered into a distribution and supply agreement with a subsidiary of Warner Chilcott Limited (NASDAQ:WCRX) to market the authorized generic version of Warner Chilcotts Dovonex Scalp Solution (calcipotriene solution 0.005%). It is indicated for the topical treatment of psoriasis of the scalp. According...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95841&full=1PORTLAND, Ore., May 8, 2008 (PRIME NEWSWIRE) -- Znomics, Inc. (OTCBB:ZNOM), a pioneer in the development of the zebrafish as a vertebrate genetic platform to accelerate drug discovery, announced today a collaborative research program with the University of Utah and its Huntsman Cancer Institute (HCI) to develop pre-clinical compounds for the treatment of T-cell leukemia, autoimmune diseases, inflammation...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95849&full=1<p> DENVER and GOLDEN, Colo., May 9 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today the finalization of new distribution agreements with LuBioScience GmbH, headquartered in Lucerne, Switzerland and Bio-Kasztel Ltd., located in Budapest, Hungary, further expanding its already extensive network of distribution partners in Europe.</p><p> LubioScience...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95857&full=1<p> EDMONTON, May 9 /PRNewswire-FirstCall/ - BioMS Medical Corp , a leading developer in the treatment of multiple sclerosis (MS), today announced an update on its pipeline products, HYC750 and development with BioCyDex Inc.</p><p> The Company has entered into a Royalty and Assignment Agreement with Orcrist Bio. Inc. for HYC750, a technology based on hyaluronic acid that has a number of potential...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95831&full=1ALACHUA, FL--(Marketwire - May 09, 2008) - Oragenics, Inc. (AMEX: ONI) announced today the test marketing of its oral probiotic product, Probiora3. The chewable tablets help to whiten teeth and improve breath though the use of a unique combination of safe, naturally occurring bacteria that are released in the mouth by chewing on a mint-flavored tablet that the Company has designed to be used twice...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95728&full=1<p> BETHESDA, Md., May 9 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. , today announced that Al Rajhi Holdings W.L.L. ("Al Rajhi") has entered into an agreement, executed on May 6 2008, to provide NWBT with debt financing in the amount of US$4.0 million (the "Loan").</p><p> Under the terms of the Loan, Northwest will receive US$4.0 million in return for an unsecured promissory note...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95747&full=1<p> NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. today announced that it had received a letter, dated May 7, 2008, from The Nasdaq Stock Market Inc. (Nasdaq) stating that the Company's common stock will be delisted from the Nasdaq Capital Market as of the opening of business on May 16, 2008 because the Company does not comply with Marketplace Rule 4310(c)(3) which...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95809&full=1PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (AMEX:LCI) announced today its chairman, William Farber, has sold five million shares of Lannett Company common stock to Farber Properties Group, LLC, a Limited Liability company owned and controlled by two of Farbers sons.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95832&full=1BRIDGEWATER, NJ--(Marketwire - May 9, 2008) - Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company, today announced the filing of its Form 10-Q for the quarter ended March 31, 2008. First quarter 2008 results include a net gain of $209.5 million, or earnings per share ("EPS") of $4.85, related to the sale of the Active Pharmaceutical Ingredients business. The reported gain reflects...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95839&full=1BOTHELL, Wash., May 9, 2008 (PRIME NEWSWIRE) -- Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) today announced that it has received a determination letter from The Nasdaq Stock Market ("Nasdaq") dated May 6, 2008, indicating that the Company has failed to regain compliance with the $1.00 minimum bid price requirement for continued listing under Marketplace Rule 4450(a)(5). The Company was first notified...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95786&full=1PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ:STEM) announced today that it welcomes and supports the National Neurotechnology Inititative Act, and its goal of fostering new discoveries and accelerating the development of new and safer treatments for brain-related injury or disease. The bill, introduced a few days ago by a bipartisan group of members of both houses of Congress, aims to...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95811&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (Nasdaq: BIIB) today commenced the mailing of proxy materials encouraging shareholders to vote at the companys June 19, 2008 Annual Meeting for four highly regarded and accomplished individuals nominated for election by the Board of Directors. In the proxy materials, shareholders are advised by the Board to reject the three director nominees proposed...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95869&full=1ROCHESTER, N.Y., May 9, 2008 (PRIME NEWSWIRE) -- VirtualScopics, Inc. (Nasdaq:VSCP), a leading provider of advanced medical imaging for clinical trials, today announced the results of its annual stockholders' meeting held on May 8, 2008 in New York City. The stockholders elected all of the nominees put forward by the board of directors for a one year term: Colby Chandler, Robert Klimasewski, Sidney...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95861&full=1<p> BASINGSTOKE, England and PHILADELPHIA, May 9 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, announces that ordinary shareholders approved the scheme of arrangement proposed in a circular to shareholders dated 16 April 2008 (the "Circular"), without modification, at a meeting convened by the Court and held today.</p><p> At a hearing convened for 22 May...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95870&full=1VANCOUVER, May 9 /CNW/ - CRH Medical Corporation (CRM:TSX-V) announcedtoday that it has opened a Center for Colorectal Health in Dallas TX. ThisCenter is the Company's first in the Dallas area, one of many new markets thatCRH has targeted for expansion. The opening of the Dallas location representsthe 5th new Center opened in 2008 bringing the Company's total number ofCenters to 13.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95775&full=1LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today financial results for the three months ended March 31, 2008. The Company reported a net loss of $697,000, or $0.02 per share, compared to a loss of $544,000, or $0.02 per share, for the three months ended March 31, 2007, an increase of 28%.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95797&full=1WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ: ACUS) today reported financial results for the first quarter ended March 31, 2008 and commented on its financial results and business highlights.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95800&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter of 2008, and company highlights.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95808&full=1PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the first quarter ended March 31, 2008. The net loss for the first quarter of 2008 was $15.6 million compared to a net loss of $7.2 million for the first quarter of 2007.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95810&full=1LAKE SUCCESS, N.Y.--(BUSINESS WIRE)--Aceto Corporation (NASDAQ:ACET), a global leader in the sourcing, regulatory support, marketing and distribution of chemically derived pharmaceuticals, biopharmaceuticals, specialty chemicals and crop protection products, today announced results of operations for its fiscal third quarter and nine months ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95830&full=1MONTREAL, QUEBEC--(Marketwire - May 09, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) announced today that it will be hosting a conference call and webcast on Wednesday, May 14, 2008, at 9:00 am ET, to discuss the financial results for the first quarter ended March 31, 2008, and provide an update on the strategy execution. Prior to the conference call, a press release will be issued on Wednesday, May...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95842&full=1CLEVELAND, May 8, 2008 (PRIME NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the quarter ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95854&full=1<p> CRANBURY, N.J., May 8 /PRNewswire-FirstCall/ -- Amicus will announce first quarter 2008 financial results after the regular close of markets on Tuesday, May 13, 2008. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.</p><p> Interested participants and investors may access the conference call at 5 p.m. EDT by dialing 877-397-02...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95738&full=1<p> DANBURY, Conn., May 9 /PRNewswire-FirstCall/ -- Biodel Inc. today reported financial results for its second quarter ended March 31, 2008. The net loss for the quarter was $9.6 million or $0.43 per share.</p><p> "We remain on track in our development of VIAject(TM)," stated Dr. Solomon Steiner, CEO and Chairman of Biodel. "The last patient visits for both pivotal Phase III clinical trials...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95741&full=1<p> BELLEVILLE, ON, May 9 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the third quarter of its 2008 fiscal year, ending March 31, 2008.</p><p> "One highlight of our third quarter was the notification by the U.S. Department of Agriculture (USDA) that our E. coli O157:H7 cattle...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95744&full=1<p> BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced financial results for the quarter ended March 31, 2008. The Company reported revenues of $10.8M in the first quarter of 2008, compared to $9.2M in the first quarter of 2007. The net loss for the quarter ended March 31, 2008 was $13.1M, or $0.34 per share, compared to a net loss for the quarter...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95758&full=1<p> TORONTO, May 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2008 first quarter operational and financial results.</p><p> Operational Highlights</p><p> During the three months ended March 31, 2008, the Company achieved the following steps in preparation for...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95769&full=1FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three months ended March 31, 2008. For the three months ended March 31, 2008, the Company reported net income of $31.3 million, or $1.62 per diluted share, compared to a net loss of $5.7 million, or $(0.34) per diluted share, for the same period in 2007. The Company...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95750&full=1<p> SEATTLE, May 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) reported financial results for the quarter ended March 31, 2008. Total revenues for the quarter were $3.4 million compared to $20,000 for the first quarter of 2007. Gross product sales of Zevalin(R) (Ibritumomab Tiuxetan) reached $3.8 million in the first quarter of 2008.</p><p> Total operating expenses increased to ...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95762&full=1<p> HOPKINTON, Mass., May 8 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. today reported its first quarter financial results for 2008. First quarter revenues were $29.3 million, an increase of 3% over revenues of $28.4 million in the same period in 2007. The effect of foreign exchange on revenues was a favorable impact of 3% compared to the prior year. Net loss for the quarter was $9....Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95792&full=1LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (NASDAQ: CRTX), a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95812&full=1COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (NASDAQ: CLN) today announced financial results for the first quarter ended March 31, 2008. The Company reported a net loss of $4.1 million, or $0.40 per share, compared to a net loss of $2.4 million, or $0.30 per share, for the first quarter of 2007. The results for 2007 included income from discontinued operations of $0.9 million, or $0.08 per share...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95868&full=1BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)(NASDAQ:CYCCP) announced today financial and operating results for the first quarter of 2008. The Companys net loss for the quarter was $6.3 million or $0.31 per share. As of March 31, 2008, the company had $49.0 million in cash, cash equivalents and short-term investments.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95751&full=1<p> MONTREAL, May 9 /PRNewswire-FirstCall/ - DRAXIS Health Inc. reported first quarter financial results for the three months ended March 31, 2008. Revenues and earnings for the first quarter of 2008 were below those in the first quarter of 2007 as a result of lower sales of sterile products, the negative impact of a significantly stronger Canadian dollar relative to the first quarter of 200...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95760&full=1<p> SEATTLE, May 8 /PRNewswire-FirstCall/ -- Dendreon Corporation today reported results for the first quarter ended March 31, 2008. Revenue for the first quarter of 2008 was $31,000 compared to $80,000 for the quarter ended March 31, 2007.</p><p> Dendreon's total operating expenses for the three months ended March 31, 2008 were $19.2 million compared to $32.0 million for the same period in...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95799&full=1MORRISVILLE, N.C.--(BUSINESS WIRE)--etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical software and services that optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint, announced financial results for the three months ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95838&full=1AMSTERDAM, Netherlands, May 9, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, today announced key achievements and financial results for the first quarter of 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95774&full=1MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced that the Company will hold a conference call on May 15, 2008 at 2 PM CET/8 AM ET to discuss its financial results for the first quarter of 2008 and provide an update on the Companys business. The results will be published on May 15 in advance of the conference...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95782&full=1GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) today announced its financial results for the first quarter ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95851&full=1<p> BERKELEY HEIGHTS, N.J., May 8 /PRNewswire-FirstCall/ -- Genta Incorporated today announced financial results for the quarter ended March 31, 2008. From the beginning of the year, the Company has recorded significant milestones including the following:</p><p></p><p> "Genta has successfully diversified with three high-value clinical-stage products in our portfolio," noted Dr. Raymond P. Warrell...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95813&full=1ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV) today reported financial results for the first quarter ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95858&full=1<p> SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today reported financial results for the three months ended March 31, 2008.</p><p> "This year is off to a solid start as we significantly advanced both our partnered and proprietary programs in the first quarter of...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95722&full=1<p> TUCSON, Ariz., May 7 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. today announced that the Company will host a live webcast and conference call on Tuesday, May 13, 2008, at 5:00 p.m. ET to discuss first quarter 2008 financial results.</p><p> The live webcast can be accessed through ImaRx's corporate website at www.imarx.com and will be archived on the website for 14 days following...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95850&full=1<p> RICHMOND, Va., May 8 /PRNewswire-FirstCall/ -- Insmed Inc. , a developer of follow-on biologics (FOB) and biopharmaceuticals, today reported results for the first quarter ended March 31, 2008.</p><p></p><p> "We continue to be pleased with the progress achieved in both our FOB and IPLEX(TM) programs," said Geoff Allan, President and CEO of Insmed. "We are aggressively pursuing a partner for...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95852&full=1<p> IRVINE, Calif., May 8 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. today reported financial results for the quarter ended March 31, 2008. Financial information presented represents the consolidated results of IDM Pharma, Inc. and its subsidiary, IDM Pharma S.A.</p><p> Total revenues for the quarter were $2.4 million, and net loss was $12.1 million or $0.48 per share for the quarter. Expenses...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95779&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (AMEX: JAV) announced today that its CEO, Martin J. Driscoll, and Stephen J. Tulipano, CPA, CFO, will host a conference call to discuss the Company's quarterly results for the period ending March 31, 2008. The call will be held Wednesday, May 14, 2008 at 8:30 a.m. EDT.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95855&full=1<p> NEW YORK, May 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. will hold a conference call on Monday, May 12, 2008 at 8:30 a.m. EDT to discuss the first quarter 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95843&full=1SCOTTSDALE, Ariz., May 8, 2008 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) today announced revenues for the three months ended March 31, 2008 of approximately $131.3 million, compared to approximately $95.1 million for the three months ended March 31, 2007, representing an increase of approximately 38%. This increase was primarily due to the strength of our acne product category, which includes SOLODYN...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95859&full=1<p> PITTSBURGH, May 8 /PRNewswire-FirstCall/ -- Mylan Inc. today announced its financial results for the three months ended March 31, 2008, the first quarter of its fiscal year ending December 31, 2008.</p><p></p><p> "I'm pleased with our first quarter results," said Mylan Vice Chairman and CEO Robert J. Coury. "Our positive performance was driven by the strong results of all three of our geographic...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95729&full=1<p> EMERYVILLE, Calif., May 8 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , today announced it will release its third quarter 2008 financial results, for the quarter ended March 31, 2008, on May 12, 2008 and host a conference call on May 13, 2008.</p><p> Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Matthew M. Loar, Vice President...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95764&full=1<p> ROCKVILLE, Md., May 9 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced financial results for the first quarter 2008. Novavax reported a net loss of $7.8 million ($0.13 loss per share) for the first quarter of 2008 compared to a net loss of $8.4 million ($0.14 loss per share) for the first quarter of 2007. Total cash and short-term investments as of March 31, 2008 were $40.9 million...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95798&full=1BOTHELL, Wash.--(BUSINESS WIRE)--Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95802&full=1HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (NasdaqGM:NTEC) today announced financial results for the first quarter ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95845&full=1ROCKVILLE, Md., May 8, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its first quarter financial results for the three month period ended March 29, 2008. The Company reported a net loss from continuing operations of $6.7 million, or $0.13 per share, compared to a net loss of $13.9 million, or $0.23 per share, for the period ended March 31, 2007. Including results from...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95770&full=1NEW YORK--(BUSINESS WIRE)--Omrix Biopharmaceuticals, Inc. (Omrix or the Company) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced financial results for the first quarter ended March 31, 2008:Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95772&full=1COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today its results for the first quarter of 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95795&full=1SAN DIEGO--(BUSINESS WIRE)--Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced unaudited financial results for the three months ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95737&full=1<p> MOUNTAIN VIEW, Calif., May 8 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services designed to optimize clinical drug development, today announced financial results for its fiscal fourth quarter and full year 2008, ended March 31, 2008. Revenue for the fiscal fourth quarter was $7.6 million, a new quarterly high for the company, and a 5% increase...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95767&full=1TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the quarter ended March 31, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95794&full=1SADDLE RIVER, N.J.--(BUSINESS WIRE)--PDI, Inc. (NASDAQ:PDII), a provider of commercialization services to the biopharmaceutical industry, today announced financial results for the three months ended March 31, 2008, and provided a business update. Summary results are as follows:Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95822&full=1MONTREAL, CANADA--(Marketwire - May 08, 2008) - Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, will release its first quarter financial results on Thursday, May 15, 2008 prior to market opening. Following the release, Paladin will hold a conference call at 10:00 a.m. (EST) hosted by Jonathan Ross Goodman, President and CEO of Paladin Labs. Paladin cordially invites...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95825&full=1REDWOOD CITY, CA--(Marketwire - May 08, 2008) - PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the quarter ended March 31, 2008. The results of the company's commercial and cardiovascular operations segment are presented as discontinued operations. The assets related to this segment were sold in March 2008. The financial results for continuing and discontinued operations...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95853&full=1<p> CRANBURY, N.J., May 8 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. will announce its third quarter, fiscal year 2008 financial results for the period ended March 31, 2008 before the open of the U.S. financial markets on May 13, 2008.</p><p> The Company will also conduct a teleconference and live audio webcast hosted by Palatin's executive management team on May 13, 2008 at which...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95773&full=1EWING, N.J.--(BUSINESS WIRE)--Redpoint Bio Corporation (OTCBB: RPBC), a company developing ingredients to improve the taste of pharmaceutical, food and beverage products, today announced financial and operational results for the first quarter ended March 31, 2008. Recent highlights included:Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95732&full=1<p> CALGARY, May 9 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced its 2008 first quarter operational and financial results.</p><p></p><p> SemBioSys is currently conducting all the necessary preclinical work for safflower-produced insulin to enable it to file an...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95768&full=1LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it will release its first-quarter 2008 financial results before the market opens on Wednesday, May 14, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95793&full=1MORRISVILLE, N.C.--(BUSINESS WIRE)--Trimeris, Inc. (Nasdaq: TRMS) today announced financial results for the quarter ended March 31, 2008, reporting net income of $2.3 million, or $0.10 per share. This compares to adjusted net income for the quarter ended March 31, 2007 of $3.8 million, or $0.17 per share, excluding the impact of two non-recurring events in the first quarter of 2007, or $8.2 million...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95803&full=1<p> SEATTLE, May 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. today announced financial results for its first quarter ended March 31, 2008.</p><p> First Quarter 2008 Financial Results</p><p> Revenue for the first quarter ended March 31, 2008, was $4.0 million, compared with $4.8 million in 2007. The decrease was primarily due to an extension of the recognition of the up-front...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95856&full=1<p> PALO ALTO, Calif., May 8 /PRNewswire-FirstCall/ -- Telik, Inc. today reported a net loss of $9.8 million, or $0.19 per share, for the first quarter ended March 31, 2008, compared with a net loss of $16.3 million, or $0.31 per share, for the comparable period in 2007.</p><p> For the quarter ended March 31, 2008, total operating costs and expenses were $10.6 million, compared with $18.0 million...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95735&full=1<p> SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Vical Incorporated today reported financial results for the quarter ended March 31, 2008. Revenues for the first quarter of 2008 were $1.9 million, compared with revenues of $1.3 million for the first quarter of 2007. The net losses for the first quarters of both 2008 and 2007 were $9.6 million, or $0.24 per share.</p><p> Vical had cash and investments...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95801&full=1MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced its financial results and highlights for the first quarter of 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95739&full=1<p> ST. DAVID'S, Bermuda, May 9 /PRNewswire-FirstCall/ -- Warner Chilcott Limited today announced its results for the quarter ended March 31, 2008. Revenue in the quarter ended March 31, 2008 totaled $229.5 million, an increase of 5.1%, over the prior year quarter. The primary drivers of the increase in revenue were the net sales of our promoted products LOESTRIN 24 FE, DORYX, TACLONEX and FEMCON...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95806&full=1VALLEY FORGE, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE:ABC) today announced a more streamlined organizational structure designed to drive increased efficiency and effectiveness and better position the Company to continue to achieve its long-term financial goals.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95726&full=1<p> SAN DIEGO, May 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. , a company focused on the discovery and development of small- molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout, today announced that John W. Beck has been appointed Senior Vice President, Finance and Operations and Chief Financial Officer effective May 27, 2008. He will resign...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95828&full=1EWING, NJ--(Marketwire - May 09, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company, announced today that its President and Chief Executive Officer Christopher J. Schaber, PhD, has joined the Board of Directors of the Alliance for Biosecurity, a collaboration among leading biosecurity research organizations and select biopharmaceutical companies...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95730&full=1<p> SOUTHFIELD, Mich., May 9 /PRNewswire/ -- Dr. Michael W. Long recently was named the third-annual Grant Thornton Leader and Innovator of the Year. The "Leader & Innovator" award recognizes and rewards leaders and innovators in the state of Michigan who have demonstrated or created unique ideas, products or abilities that generate a better quality of life in our communities. Nominees were recognized...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95736&full=1<p> NUTLEY, N.J., May 9 /PRNewswire/ -- Roche announced today that Sarah Vidal, M.P.H., product director, Rheumatoid Arthritis Marketing at Roche, was honored as a 2008 Rising Star by the Healthcare Businesswomen's Association (HBA) at the organization's annual awards luncheon on May 8, 2008 in New York City.</p><p> "Sarah has made significant contributions at Roche. Her combination of confidence...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95780&full=1SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentations at the following upcoming conferences:Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95785&full=1SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced its presentation at Bairds 2008 Growth Stock Conference on Tuesday, May 13, 2008 at 11:50 a.m. CDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer will provide an overview of the...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95866&full=1MORRISTOWN, N.J. Diversity Alliance for Science (www.diversityallianceforscience.com) has announced the release of a podcast discussing what attendees can expect at the 2008 inaugural conference and expo scheduled for May 19-20 at the Westin Governor Morris in Morristown, N.J. In the podcast, Alison Macpherson, president of Bright Pharmaceutical Services, Inc. and Diversity Alliance for Science...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95789&full=1BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Banc of America Securities Healthcare Conference on May 13 in Las Vegas. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95791&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by Bank of America Securities on Wednesday, May 14, 2008 at 7:00 p.m. ET (4:00 p.m. PT). The presentation will be webcast from the Four Seasons Hotel in Las Vegas, Nevada and may be accessed under the investor relations tab at www.alkermes.com. The presentation will...Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95807&full=1ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) announced today that it will present and provide an audio webcast of its corporate presentation at the Bank of America 2008 Healthcare Conference on Wednesday, May 14, 2008.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95827&full=1BRIDGEWATER, NJ--(Marketwire - May 09, 2008) - Alpharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, announced today that senior management will provide an overview of the company's business at the Bank of America Healthcare Conference on Wednesday, May 14, 2008 at 8:00 AM Pacific Time. The conference will be held at The Four Seasons Hotel in Las Vegas, Nevada.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95846&full=1THE WOODLANDS, Texas, May 8, 2008 (PRIME NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that a member of Lexicon senior management will present at the Bank of America Health Care Conference at the Four Seasons Hotel in Las Vegas, Nevada on Wednesday, May 14, 2008 at 2:00 p.m. Pacific Time.Fri, 09 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95499&full=1TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE/TSX: BVF) today announced several new initiatives stemming from its strategic review, including a new strategic focus on developing specialty products targeted towards central nervous system (CNS) disorders intended to drive sustainable growth. The Company also announced Board approval for the filing of a Normal Course Issuer Bid for up to 14 million...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95514&full=1INDIANAPOLIS, May 8 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY - News) announced today that the United States Food and Drug Administration (FDA) has approved Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95506&full=1COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR - News) today announced it has been given clearance by the U.S. Food and Drug Administration (FDA) to initiate an expanded access treatment program for Prochymal, making the investigational stem cell product available to children with life-threatening Graft vs. Host Disease (GvHD). Prochymal, a formulation of adult mesenchymal stem...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95510&full=1WOODCLIFF LAKE, N.J., May 7 /PRNewswire/ -- Eisai Corporation of North America and its U.S. subsidiary, MGI PHARMA, INC., today announced that the U.S. Food and Drug Administration (FDA) Advisory Committee on Anesthetic and Life Support Drugs (ALSDAC) has voted 6 to 3 in favor (with one abstention) of approval of fospropofol disodium injection for use as an intravenous sedative-hypnotic agent for sedation...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95501&full=1TAMPA, May 8 /PRNewswire-FirstCall/ -- New Phase III study data showed that Abbott's investigational hydrocodone bitartrate and acetaminophen (HC/APAP) extended release medicine reduced pain in patients with moderate to severe chronic low back pain, one of the most common causes of chronic pain. Taken twice daily in the clinical trial, Vicodin CR(TM) (HC/APAP extended release) significantly lowered...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95508&full=1BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY - News) today announced that its Chief Medical Officer, John Yates, M.D., presented additional positive results from a Phase 2 clinical trial evaluating the efficacy of ARRY-797, a novel small molecule pan-cytokine inhibitor, in patients with post-surgical dental pain at the American Pain Societys 27th Annual Scientific Meeting in...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95507&full=1LOS ANGELES, May 7 (Reuters) - A panel of expert advisers to the U.S. Food and Drug Administration will meet at the end of this month to review GlaxoSmithKline Plc's experimental drug for treating a disorder in which the blood does not clot properly, according to Amgen Inc.Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95503&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 213,888 unregistered shares of Alnylams common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.</p><p>In connection...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95518&full=1<p> FREDERICK, Md., May 7 /PRNewswire/ -- Vaccinogen Inc. said Dutch health authorities licensed it to manufacture its break-through OncoVAX anti-colon cancer vaccine, immediately clearing the path to more than $100 million of potential European sales.</p><p> The Dutch approval of the company's facility based in Emmen, The Netherlands also paves the way to its pivotal US FDA Phase IIIb clinical...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95500&full=1WILMINGTON, Del., May 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN - News) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of generalized anxiety disorder (GAD), including maintenance of antianxiety effect. It is the...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95504&full=1RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI - News) and commercial partner Meda Pharmaceuticals will present today and tomorrow, data from Phase III clinical pivotal trials for BEMA Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid tolerant patients with cancer. The presentations will be made at the 27th Annual Scientific Meeting of the...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95530&full=1<p> LEVERKUSEN, Germany, MONTVILLE, New Jersey and TARRYTOWN, New York, May 8 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. today announced that the first patient has been dosed in the VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of Age-related Macular Degeneration ...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95531&full=1<p> SMYRNA, Ga., May 8 /PRNewswire/ -- Patients treated with lacosamide demonstrated sustained pain relief from diabetic neuropathic pain (DNP), compared to placebo-treated patients, according to data presented at the 27th annual meeting of the American Pain Society (APS) in Tampa, Fla.</p><p> "This is the first placebo-controlled trial of a diabetic neuropathic pain treatment providing evidence...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95609&full=1<p> WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints.</p><p> "Adults with ADHD often find it challenging to focus and...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95615&full=1BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that three abstracts related to the companys development program for GATTEX (teduglutide) for intestinal failure associated with short bowel syndrome (SBS) were accepted for presentation at the 2008 Digestive Disease Week (DDW) conference in San Diego May 17-22, 2008. The results from a Phase 3 study of GATTEX...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95616&full=1BOSTON & PERTH, Australia--(BUSINESS WIRE)--pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(FSE:PSI) announced today that enrollment has begun for a clinical trial to assess the safety and efficacy of Medidur FA in conjunction with Lucentis (ranibizumab injection, Genentech) in patients with exudative age-related macular degeneration (wet AMD). The study is designed to provide preliminary information on the...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95625&full=1EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), today announced positive interim data from the ongoing pegloticase open label extension (OLE) to the Phase 3 pivotal trials in patients with treatment-failure gout. The interim results are based on the OLE data cut at the end of September 2007.Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95502&full=1BRISBANE, Calif., May 8 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on-going trials in breast and brain cancer.</p><p>The company is evaluating BSI-201, the first poly ADP-ribose polymerase...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95532&full=1<p> CAMBRIDGE, Mass., May 7 /PRNewswire-FirstCall/ -- Genzyme Corp. reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound produced a meaningful impact on key clinical manifestations of Gaucher disease. The results highlight the potential of this compound to become an innovative...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95555&full=1<p> NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. today announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial is being conducted...Thu, 08 May 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=95597&full=1HASBROUCK HEIGHTS, NJ--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that a large new 3 year follow-up study of NX-1207 for benign prostatic hyperplasia (BPH) is near completion. The study evaluated symptomatic progress of over one hundred subjects involved in the Companys Phase 2 U.S. clinical trial initiated in 2005. Individuals in the study were assessed 3 years...Thu, 08 May 2008 12:00:00 AM GMT